Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovative Pharmaceutical Biotech ( (HK:0399) ) just unveiled an update.
Starcoin Group Limited announced that the Hong Kong High Court has refused its application for leave to pursue a judicial review of a Listing Review Committee decision, which found the company failed to maintain sufficient operations under listing rules. As a result, the court also declined to grant interim injunctive relief to stay implementation of that decision.
With the expiry of an earlier interim injunction and no further stay granted, the company requested suspension of trading in its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on 6 May 2026. The board cautioned shareholders and potential investors to exercise care when dealing in the company’s securities and said further announcements will follow in line with listing requirements.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is listed on the Hong Kong Stock Exchange and is incorporated in the Cayman Islands and continued in Bermuda with limited liability. The group had been under regulatory scrutiny for failing to maintain a sufficient level of operations as required under the exchange’s listing rules, triggering multiple reviews by listing authorities.
Average Trading Volume: 53,918,018
Technical Sentiment Signal: Sell
Current Market Cap: HK$174.2M
Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.